$53.31 4.2%
HALO Stock Price vs. AI Score
Data gathered: June 3

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Halozyme Therapeutics (HALO)

Analysis generated November 16, 2024. Powered by Chat GPT.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company focused on developing and commercializing oncology and drug-delivery therapies. Halozyme partners with pharmaceutical and biotechnology companies to apply its proprietary ENHANZE® technology, an enzyme-based drug delivery system, to improve the efficacy and efficiency of injectable drugs and biologics. The company’s innovative approaches and collaborations have positioned it as a key player in the drug delivery market.

Read full AI stock Analysis

Stock Alerts - Halozyme Therapeutics (HALO)

company logo Halozyme Therapeutics | May 16
Price is up by 7% in the last 24h.
company logo Halozyme Therapeutics | May 13
Price is down by -14.8% in the last 24h.
company logo Halozyme Therapeutics | May 7
Price is up by 8.6% in the last 24h.
company logo Halozyme Therapeutics | April 29
Insider Alert: Henderson Jeffrey William is selling shares

Download our app to get future alerts delivered in real-time.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.


Halozyme Therapeutics
Price $53.31
Target Price Sign up
Volume 3,060,000
Market Cap $6.91B
Year Range $42.57 - $70.14
Dividend Yield 0%
PE Ratio 14.91
Analyst Rating 43% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '25265M48M216M118M169M1.110
Q4 '24298M42M256M137M203M1.260
Q3 '24290M49M241M137M190M1.270
Q2 '24231M57M174M93M138M0.910
Q1 '24196M46M150M77M116M0.790

Insider Transactions View All

Henderson Jeffrey William filed to sell 28,611 shares at $61.
April 28 '25
Henderson Jeffrey William filed to sell 28,811 shares at $60.3.
April 28 '25
Henderson Jeffrey William filed to sell 33,108 shares at $64.1.
April 1 '25
Henderson Jeffrey William filed to sell 36,816 shares at $57.9.
March 3 '25
Henderson Jeffrey William filed to sell 33,611 shares at $59.1.
March 3 '25

Congress Trading View All

Politician Filing Date Type Size
Gil Cisneros
Apr 8, 25 Sell $1K - $15K
Daniel S. Goldman
Democrat
Aug 13, 23 Sell $15K - $50K

What is the Market Cap of Halozyme Therapeutics?

The Market Cap of Halozyme Therapeutics is $6.91B.

What is Halozyme Therapeutics' PE Ratio?

As of today, Halozyme Therapeutics' PE (Price to Earnings) ratio is 14.91.

What is the current stock price of Halozyme Therapeutics?

Currently, the price of one share of Halozyme Therapeutics stock is $53.31.

How can I analyze the HALO stock price chart for investment decisions?

The HALO stock price chart above provides a comprehensive visual representation of Halozyme Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Halozyme Therapeutics shares. Our platform offers an up-to-date HALO stock price chart, along with technical data analysis and alternative data insights.

Does HALO offer dividends to its shareholders?

As of our latest update, Halozyme Therapeutics (HALO) does not offer dividends to its shareholders. Investors interested in Halozyme Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Halozyme Therapeutics?

Some of the similar stocks of Halozyme Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Chat with AltIndex AI

👋 Welcome to AltIndex AI Chat!

Ask about:
  • Stock performance
  • AI score insights
  • Trending investment opportunities
  • How to use AltIndex
You need to log in to use AltIndex AI Chat.
Disclaimer: AI outputs may be incorrect. This is for informational purposes only and not a substitute for professional financial advice.